Chemical formula: C₅₈H₇₃N₇O₁₇ Molecular mass: 1,140.237 g/mol PubChem compound: 166548
Anidulafungin interacts in the following cases:
Infusion-related adverse events have been reported with anidulafungin, including rash, urticaria, flushing, pruritus, dyspnoea, bronchospasm and hypotension. Infusion-related adverse events are infrequent when the rate of anidulafungin infusion does not exceed 1.1 mg/min.
There are no data from the use of anidulafungin in pregnant women. Studies in animals have shown reproductive toxicity.
Anidulafungin is not recommended during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the foetus.
It is unknown whether anidulafungin is excreted in human milk. Available pharmacodynamic/toxicological data in animals have shown excretion of anidulafungin in milk.
A risk to the suckling child cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from anidulafungin therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
For anidulafungin, there were no effects on fertility in studies conducted in male and female rats.
Not relevant.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
